Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 4/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357988 | 0.81 | TNF (0.46) | P2RX7TNFRIPK1NR3C1PGR | |
| SCHEMBL20939366 | 0.81 | P2RX7 (0.42) | P2RX7AURKATPX2PRKCQPRKCD | |
| SCHEMBL24786395 | 0.78 | TNF (0.43) | P2RX7TNFRIPK1ARAHR | |
| SCHEMBL1146475 | 0.78 | P2RX7 (0.40) | P2RX7AURKATPX2PRKCQPRKCD | |
| SCHEMBL18876102 | 0.75 | AURKA (0.36) | TNFRIPK1AURKATPX2PRKCQ | |
| SCHEMBL12748352 | 0.75 | TNF (0.38) | P2RX7TNFRIPK1NR3C1PGR | |
| SCHEMBL26145363 | 0.74 | AURKA (0.34) | P2RX7AURKATPX2 | |
| SCHEMBL26145674 | 0.73 | AURKA (0.36) | P2RX7TNFRIPK1AURKATPX2 | |
| SCHEMBL24215565 | 0.73 | TNF (0.41) | P2RX7TNFRIPK1NR3C1PGR | |
| SCHEMBL15797379 | 0.73 | AURKA (0.58) | P2RX7AURKATPX2PRKAA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | P2RX7 4849/4885TNF 3331/4885RIPK1 2929/4885 |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | P2RX7 2432/4885TNF 690/4885RIPK1 3714/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | P2RX7 4865/4885TNF 2693/4885RIPK1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.